CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial
Publication
, Conference
Choueiri, TK; Halabi, S; Sanford, B; Hahn, O; Michaelson, MD; Walsh, M; Olencki, T; Picus, J; Small, EJ; Dakhil, S; George, D; Morris, MJ
Published in: Annals of Oncology
October 1, 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi566
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Choueiri, T. K., Halabi, S., Sanford, B., Hahn, O., Michaelson, M. D., Walsh, M., … Morris, M. J. (2016). CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. In Annals of Oncology (Vol. 27, p. vi566). https://doi.org/10.1093/annonc/mdw435.23
Choueiri, T. K., S. Halabi, B. Sanford, O. Hahn, M. D. Michaelson, M. Walsh, T. Olencki, et al. “CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial.” In Annals of Oncology, 27:vi566, 2016. https://doi.org/10.1093/annonc/mdw435.23.
Choueiri TK, Halabi S, Sanford B, Hahn O, Michaelson MD, Walsh M, et al. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. In: Annals of Oncology. 2016. p. vi566.
Choueiri, T. K., et al. “CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial.” Annals of Oncology, vol. 27, 2016, p. vi566. Scopus, doi:10.1093/annonc/mdw435.23.
Choueiri TK, Halabi S, Sanford B, Hahn O, Michaelson MD, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, George D, Morris MJ. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. Annals of Oncology. 2016. p. vi566.
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi566
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis